Acute Pain Pipeline, Clinical and Non-Clinical Stages Products, and FDA Approvals 2023 (Updated)
DelveInsight’s, “Acute Pain Pipeline Insight 2023” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in the Acute Pain pipeline landscape. It covers the Acute Pain pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Acute Pain pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Acute Pain Pipeline Report
- DelveInsight’s Acute Pain pipeline report depicts a robust space with 25+ active players working to develop 25+ pipeline therapies for Acute Pain treatment.
- The leading companies working in the Acute Pain Market include Neumentum, CGeneTech, Algomedix, TREMEAU PHARMACEUTICALS, Vertex Pharmaceuticals, Kures Inc., Jiangsu Hengrui Medicine Co., SiteOne Therapeutics, Mylan Specialty, LP, Viatris Inc., Tetra Bio-Pharma, Scilex Pharmaceuticals, Inc., and others.
- Promising Acute Pain Pipeline Therapies in the various stages of development include Diclofenac Sodium Patch, Methoxyflurane, Tramadol 50, Diclofenac 50, VX-548, HB/APAP, Naproxen, and others.
- August 2023: Xgene Pharmaceutical Group announced a study of phase 2 & 3 clinical trials for XG005 tablet. This study will evaluate the safety, efficacy, and PK of low dose (750 mg) and high-dose (1250 mg) XG005 oral tablets compared with placebo in subjects undergoing bunionectomy. Subjects will be confined in the clinic from check-in through 72 hours post-surgery to monitor subject safety.
- September 2023: Elysium Therapeutics Inc. announced a study of phase 1 clinical trials for ETR028, ETR029, [ETR028 + ETR029] or HCBT. The goal of this Phase 1 clinical study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of O2P (Oral Overdose Protected) hydrocodone prodrugs (ETR028 and ETR029) relative to hydrocodone bitartrate hemipentahydrate (HCBT) comparator following single oral doses in healthy adult subjects under fasted and fed conditions with naltrexone blockade.
Request a sample and discover the recent advances in Acute Pain Treatment Drugs @ Acute Pain Pipeline Report
In the Acute Pain pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute Pain collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Acute Pain Overview
Pain is an unpleasant sensory and emotional experience usually arising from actual or potential tissue damage. Acute pain can be a difficult medical problem to diagnose and treat. It may be caused by many events or circumstances. Symptoms can last hours, days, or weeks and are commonly associated with tissue injury, inflammation, a surgical procedure, childbirth, or a brief disease process.
Find out more about Acute Pain Therapeutics Assessment @ Acute Pain Preclinical and Discovery Stage Products
Acute Pain Emerging Drugs Profile
- NTM-001: Neumentum
- CGT 1507: CGeneTech
- TRPA1 Antagonist: Algomedix
Acute Pain Pipeline Therapeutics Assessment
There are approx. 25+ key companies which are developing the Acute Pain therapies. The Acute Pain companies which have their Acute Pain drug candidates in the most advanced stage, i.e. phase III include, Neumentum.
Learn more about the emerging Acute Pain Pipeline Therapies @ Acute Pain Clinical Trials Assessment
Scope of the Acute Pain Pipeline Report
- Coverage- Global
- Acute Pain Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Acute Pain Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Acute Pain Companies- Neumentum, CGeneTech, Algomedix, TREMEAU PHARMACEUTICALS, Vertex Pharmaceuticals, Kures Inc., Jiangsu Hengrui Medicine Co., SiteOne Therapeutics, Mylan Specialty, LP, Viatris Inc., Tetra Bio-Pharma, Scilex Pharmaceuticals, Inc., and others.
- Acute Pain Pipeline Therapies- Diclofenac Sodium Patch, Methoxyflurane, Tramadol 50, Diclofenac 50, VX-548, HB/APAP, Naproxen, and others.
Dive deep into rich insights for new drugs for Acute Pain treatment, Visit @ Acute Pain Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Acute Pain Executive Summary
- Acute Pain: Overview
- Acute Pain Pipeline Therapeutics
- Acute Pain Therapeutic Assessment
- Acute Pain– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- NTM-001: Neumentum
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Drug name : Company name
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Drug name : Company name
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- TRPA1 Antagonist: Algomedix
- Drug profiles in the detailed report…..
- Inactive Products
- Acute Pain Key Companies
- Acute Pain Key Products
- Acute Pain- Unmet Needs
- Acute Pain- Market Drivers and Barriers
- Acute Pain- Future Perspectives and Conclusion
- Acute Pain Analyst Views
- Acute Pain Key Companies
- Appendix
For further information on the Acute Pain pipeline therapeutics, reach out to Acute Pain Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking
){kind=link}